Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis

European Journal of Neurology

Volumn 20, Issue 4, 2013, Pages 647-654

  Korner S ^a   Kollewe, K ^a   Ilsemann, J ^a   Muller Heine A ^a   Dengler, R ^a,b   Krampfl, K ^a   Petri, S ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

Amyotrophic lateral sclerosis; Cardiovascular risk factors diseases; Dementia; Depression

Indexed keywords

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL;

AGE FACTORS; AGE OF ONSET; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DIABETES COMPLICATIONS; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; MENTAL DISORDERS; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84875050496     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12015     Document Type: Article

References (41)

1. Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 2011; 10: 75-82.
2. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003; 60: 1094-1097.
3. Pradat PF, Bruneteau G, Gordon PH, et al. Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010; 11: 166-171.
4. Sutedja NA, van der Schouw YT, Fischer K, et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011; 82: 638-642.
5. Turner MR, Wotton C, Talbot K, Goldacre MJ. Cardiovascular fitness as a risk factor for amyotrophic lateral sclerosis: indirect evidence from record linkage study. J Neurol Neurosurg Psychiatry 2012; 83: 395-398.
6. Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008; 70: 1004-1009.
7. Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 2011; 258: 613-617.
8. Zoccolella S, Simone IL, Lamberti P, et al. Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurology 2008; 70: 222-225.
9. Chio A, Calvo A, Ilardi A, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 2009; 73: 1681-1685.
10. Strong MJ, Yang W. The frontotemporal syndromes of ALS. Clinicopathological correlates. J Mol Neurosci 2011; 45: 648-655.
11. Polymenidou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW, Yeo GW. Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res 2012; 1462: 3-15.
12. Lule D, Hacker S, Ludolph A, Birbaumer N, Kubler A. Depression and quality of life in patients with amyotrophic lateral sclerosis. Dtsch Arztebl Int 2008; 105: 397-403.
13. Rabkin JG, Albert SM, Del Bene ML, et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology 2005; 65: 62-67.
14. Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci 2008; 275: 69-73.
15. Hart YM, Shorvon SD. The nature of epilepsy in the general population. I. Characteristics of patients receiving medication for epilepsy. Epilepsy Res 1995; 21: 43-49.
16. Logroscino G, Traynor BJ, Hardiman O, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 2008; 79: 6-11.
17. Korner S, Kollewe K, Fahlbusch M, et al. Onset and spreading patterns of upper and lower motor neuron symptoms in amyotrophic lateral sclerosis. Muscle Nerve 2011; 43: 636-642.
18. Miller RG, Anderson FA Jr, Bradley WG, et al. The ALS patient care database: goals, design, and early results. ALS C.A.R.E. Study Group. Neurology 2000; 54: 53-57.
19. Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol 2006; 253: 1428-1436.
20. Zoccolella S, Beghi E, Palagano G, et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2008; 79: 33-37.
21. Armon C, Kurland LT, O'Brien PC, Mulder DW. Antecedent medical diseases in patients with amyotrophic lateral sclerosis. A population-based case-controlled study in Rochester, Minn, 1925 through 1987. Arch Neurol 1991; 48: 283-286.
22. Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 2011; 44: 20-24.
23. Desport JC, Preux PM, Magy L, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 2001; 74: 328-334.
24. Kim SM, Kim H, Kim JE, et al. Amyotrophic lateral sclerosis is associated with hypolipidemia at the presymptomatic stage in mice. PLoS One 2011; 6: e17985.
25. Asai H, Hirano M, Udaka F, et al. Sympathetic disturbances increase risk of sudden cardiac arrest in sporadic ALS. J Neurol Sci 2007; 254: 78-83.
26. Murata Y, Harada T, Ishizaki F, Izumi Y, Nakamura S. An abnormal relationship between blood pressure and pulse rate in amyotrophic lateral sclerosis. Acta Neurol Scand 1997; 96: 118-122.
27. Jokelainen M, Palo J. Letter: Amyotrophic lateral sclerosis and autonomic nervous system. Lancet 1976; 1: 1246.
28. Sachs C, Conradi S, Kaijser L. Autonomic function in amyotrophic lateral sclerosis: a study of cardiovascular responses. Acta Neurol Scand 1985; 71: 373-378.
29. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65: 545-551.
30. Moore MJ, Moore PB, Shaw PJ. Mood disturbances in motor neurone disease. J Neurol Sci 1998; 160(Suppl 1): S53-S56.
31. Paykel ES. Depression: major problem for public health. Epidemiol Psichiatr Soc 2006; 15: 4-10.
32. Wasserman D, Rihmer Z, Rujescu D, et al. The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry 2012; 27: 129-141.
33. Atassi N, Cook A, Pineda CM, Yerramilli-Rao P, Pulley D, Cudkowicz M. Depression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011; 12: 109-112.
34. Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010; 9: 995-1007.
35. Kaji R, Izumi Y, Adachi Y, Kuzuhara S. ALS-parkinsonism-dementia complex of Kii and other related diseases in Japan. Parkinsonism Relat Disord 2012; 18(Suppl 1): S190-S191.
36. Waring SC, Esteban-Santillan C, Reed DM, et al. Incidence of amyotrophic lateral sclerosis and of the parkinsonism-dementia complex of Guam, 1950-1989. Neuroepidemiology 2004; 23: 192-200.
37. Gilbert RM, Fahn S, Mitsumoto H, Rowland LP. Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes. Mov Disord 2010; 25: 1868-1875.
38. van Es MA, Schelhaas HJ, van Vught PW, et al. Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol 2011; 70: 964-973.
39. Boeve BF, Boylan KB, Graff-Radford NR, et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 2012; 135: 765-783.
40. Sugai F, Yamamoto Y, Miyaguchi K, et al. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 2004; 20: 3179-3183.
41. Piepers S, Veldink JH, de Jong SW, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol 2009; 66: 227-234.